Stock Chart

REPL

$7.03 -4.87%
Score: 54.7 HOLD
LEAPs: SELL $12
i
LEAPs Option Signal

Type: SELL wallstreet
Strike: $12
Premium: $3.16
Expiry: Jan 15, 2027
Target: $13
Score: -82

LEAPs are long-term options (1+ year) with less time decay.
30D Target: $4.99 - $7.03 STRONG_UPTREND
i
30D Trendline Target

This is a PROJECTED price range based on extrapolating the current trendline slope forward 30 days.

How it works:
• Draws support and resistance trendlines
• Calculates slope (rate of change)
• Projects lines to 30 days future

Signals:
● STRONG_UPTREND: Steep rise
● UPTREND: Moderate rise
● SIDEWAYS: Flat/Mixed
● DOWNTREND: Falling

⚠️ Not a prediction. Shows trend projection only.

R-squared: 0.36
Vol: 0.82x (vs SPY: 0.6x | vs QQQ: 0.7x)
Volume Ratio Explained

Vol: Current volume vs 20-day average
vs SPY: Relative activity vs market
vs QQQ: Relative activity vs tech

Color Guide:
● Red (≥1.5x): High activity
● Yellow (≥1.2x): Above average
● Blue (≤0.7x): Low activity

Interpretation:
• vs SPY > 1: Stock-specific interest
• vs SPY < 1: Stock quiet vs market
Technical Chart
CHART OVERLAYS
Active: 2
INDICATORS
TRENDLINES
OPTIONS FLOW
VOLUME & PRICE
OTHER

About REPL - Replimune Group, Inc.

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its …

Key Statistics

Market Cap $551M

This REPL stock chart provides comprehensive technical analysis including candlestick patterns, volume profile analysis, and options open interest data. Track REPL's price movements with trendlines, gamma walls, and key support/resistance levels.